A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit

NCT06805825 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

67

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastrointestinal Stromal Tumors
Small-cell Lung Cancer
Adenoid Cystic Carcinoma
Uveal Melanoma
Neuroendocrine Tumors
Chromophobe Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma

Interventions

DRUG: NN3201

Sponsor

Novelty Nobility, Inc.